Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) CFO Sells $2,745,103.68 in Stock

Key Points

• Mark W. Hahn, CFO of Verona Pharma PLC, sold 208,912 shares for approximately $2.75 million, reducing his holdings by 1.65% to 12,464,968 shares.
• Verona Pharma shares experienced price fluctuations with a 1-year high of $105.50 and a 1-year low of $19.45, alongside a current market cap of $8.97 billion.
• Analysts have downgraded Verona Pharma from a "strong-buy" rating to "hold", with a consensus price target set around $109.00.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) CFO Mark W. Hahn sold 208,912 shares of Verona Pharma PLC American Depositary Share stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $13.14, for a total value of $2,745,103.68. Following the transaction, the chief financial officer owned 12,464,968 shares of the company's stock, valued at $163,789,679.52. The trade was a 1.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Verona Pharma PLC American Depositary Share Trading Down 0.1%

Verona Pharma PLC American Depositary Share stock traded down $0.12 during trading hours on Friday, reaching $105.28. 610,545 shares of the company's stock were exchanged, compared to its average volume of 4,298,595. The firm has a market capitalization of $8.96 billion, a PE ratio of -106.34 and a beta of 0.12. The firm's 50 day simple moving average is $97.20 and its 200 day simple moving average is $75.53. The company has a quick ratio of 8.73, a current ratio of 10.71 and a debt-to-equity ratio of 0.87. Verona Pharma PLC American Depositary Share has a twelve month low of $21.56 and a twelve month high of $105.50.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.14. The business had revenue of $103.14 million for the quarter, compared to analyst estimates of $90.41 million. Verona Pharma PLC American Depositary Share had a negative return on equity of 21.12% and a negative net margin of 36.62%. Research analysts predict that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current year.

Institutional Trading of Verona Pharma PLC American Depositary Share

Several institutional investors and hedge funds have recently modified their holdings of VRNA. Raymond James Financial Inc. bought a new position in shares of Verona Pharma PLC American Depositary Share during the 4th quarter worth approximately $225,000. LPL Financial LLC lifted its position in shares of Verona Pharma PLC American Depositary Share by 108.1% during the 4th quarter. LPL Financial LLC now owns 30,033 shares of the company's stock worth $1,395,000 after buying an additional 15,598 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Verona Pharma PLC American Depositary Share by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 62,741 shares of the company's stock worth $2,914,000 after buying an additional 660 shares in the last quarter. Trexquant Investment LP bought a new position in shares of Verona Pharma PLC American Depositary Share during the 4th quarter worth approximately $1,447,000. Finally, Wells Fargo & Company MN lifted its position in shares of Verona Pharma PLC American Depositary Share by 27.2% during the 4th quarter. Wells Fargo & Company MN now owns 67,126 shares of the company's stock worth $3,117,000 after buying an additional 14,362 shares in the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Canaccord Genuity Group cut Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating and set a $107.00 price target for the company. in a research note on Wednesday, July 9th. Roth Capital cut Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 10th. TD Cowen cut Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, July 9th. Truist Financial cut Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, July 9th. Finally, HC Wainwright reiterated a "neutral" rating and issued a $107.00 price target (up from $90.00) on shares of Verona Pharma PLC American Depositary Share in a research note on Monday, July 14th. Eleven analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $109.00.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.